Would you consider adding abiraterone to ADT and salvage RT in a prostate cancer patient with pN1 disease at radical prostatectomy?

This is a question that is being addressed in the salvage setting by NRG GU008. Currently, we have high level evidence that adding abiraterone to ADT is superior to ADT alone for subsets of patients with metastatic disease and the combination with RT is superior to ADT alone plus RT for both clinical N1 disease and locally advanced cN0 disease. I would strongly encourage you to enroll your patient in the NRG trial, but if that is not feasible, it would be reasonable to have a discussion with you...